Transcoronary concentration gradients of circulating microRNAs in heart failure

Rosa, Salvatore De; Eposito, Francesca; Carella, Cristina; Strangio, Antonio; Ammirati, Giuseppe; Sabatino, Jolanda; Abbate, F.; Iaconetti, Claudio; Liguori, Vincenzo; Pergola, Valerio; Polimeni, Alberto; Coletta, Silvio; Gareri, Clarice; Trimarco, Bruno; Stabile, Giuseppe; Curcio, Antonio; Indolfi, Ciro; Rapacciuolo, Antonio

doi:10.1002/ejhf.1119

Cited by 81 publications

(73 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Correspondingly, the involvement of novel biomarkers in inflammatory processes was also observed in our study, reflected by a significant correlation of all markers with CRP. In addition to novel biomarkers tested in our project, latest studies also proposed an analysis of micro-RNA expression patterns as a novel diagnostic approach in heart failure [32][33][34]. On this regard, De Rosa et al could show, that transcoronary concentration gradients of circulating microRNAs could help to distinguish between different heart failure entities [33].…”

Section: Discussionmentioning

confidence: 89%

“…In addition to novel biomarkers tested in our project, latest studies also proposed an analysis of micro-RNA expression patterns as a novel diagnostic approach in heart failure [32][33][34]. On this regard, De Rosa et al could show, that transcoronary concentration gradients of circulating microRNAs could help to distinguish between different heart failure entities [33]. Similar to biomarkers in our study, circulating and exosomal micro-RNAs were also shown to correlate with clinical parameters such as left ventricular function in former studies [32,34].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls

Jirak

Pistulli

Lichtenauer

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Heart failure with preserved ejection fraction (HFpEF) remains an ongoing therapeutic and diagnostic challenge to date. In this study we aimed for an analysis of the diagnostic potential of four novel cardiovascular biomarkers, GDF-15, H-FABP, sST2, and suPAR in HFpEF patients compared to controls as well as ICM, and DCM. Methods: In total, we included 252 stable outpatients and controls (77 DCM, 62 ICM, 18 HFpEF, and 95 controls) in the present study. All patients were in a non-decompensated state and on a stable treatment regimen. Serum samples were obtained and analyzed for GDF-15 (inflammation, remodeling), H-FABP (ischemia and subclinical ischemia), sST2 (inflammation, remodeling) and suPAR (inflammation, remodeling) by means of ELISA. Results: A significant elevation of GDF-15 was found for all heart failure entities compared to controls (p < 0.005). Similarly, H-FABP evidenced a significant elevation in all heart failure entities compared to the control group (p < 0.0001). Levels of sST2 were significantly elevated in ICM and DCM patients compared to the control group and HFpEF patients (p < 0.0001). Regarding suPAR, a significant elevation in ICM and DCM patients compared to the control group (p < 0.0001) and HFpEF patients (p < 0.01) was observed. An AUC analysis identified H-FABP (0.792, 95% CI 0.713-0.870) and GDF-15 (0.787, 95% CI 0.696-0.878) as paramount diagnostic biomarkers for HFpEF patients. Conclusion: Based on their differences in secretion patterns, novel cardiovascular biomarkers might represent a promising diagnostic tool for HFpEF in the future.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls

Jirak

Pistulli

Lichtenauer

et al. 2020

JCM

View full text Add to dashboard Cite

show abstract

“…In combination with other researchers 'statistics on sample size, we selected more than 60 healthy samples and more than 60 cases of heart failure. Exhaustion samples were analyzed [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38]. As shown in Figure 1, the aim of the present study was to identify circulating miRNAs in human plasma as biomarkers for the diagnosis of heart failure and its related diseases, to assess the appropriate biomarkers for identifying key characteristics of miRNAs, and to analyze their performance.…”

Section: Introductionmentioning

confidence: 99%

Combined detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for screening of early heart failure diseases

Ding

Wang

et al. 2020

Bioscience Reports

View full text Add to dashboard Cite

The use of circulating microRNAs as biomarkers opens up new opportunities for the diagnosis of cardiovascular diseases because of their specific expression profiles. The aim of the present study was to identify circulating microRNAs in human plasma as potential biomarkers of heart failure and related diseases. We used real-time quantitative PCR to screen mi-croRNA in plasma samples from 62 normal controls and 62 heart failure samples. We found that circulating miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 expressed differently between healthy controls and heart failure patients. Plasma levels of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 were unaffected by hemolysis. Correlation analysis showed any two of these miRNAs possess a strong correlation, indicating a possibility of combined analysis. MiR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 could be combined in two or three or more combinations. The results suggest that miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 may be a new diagnostic biomarker for heart failure and related diseases.

show abstract

“…A number of circulating microRNAs are known to be altered in cachexia and sarcopenia [20,21]. Interestingly, among screened microRNAs, several are also candidate markers in heart failure [22,23], as well as some cachexia-related circulating microRNAs, such as microRNA-21 and microRNA-133, and are promising biomarkers in heart failure thatmight be able to help distinguish underlying etiology, including cachexia [24].…”

Section: Discussionmentioning

confidence: 99%

Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure

Sobieszek

Powrózek

Mazurek

et al. 2020

JCM

View full text Add to dashboard Cite

Background: Cachexia is an unfavorable metabolic syndrome causing involuntary weight loss followed by muscle wasting, which can lead to the exacerbation of chronic heart failure (CHF), and considerably increases mortality rate among CHF patients. Unfortunately, until now it has not been possible to determine factors that could improve clinical options for cachexia management or enable the identification of patients at risk of its development. We assessed how cachexia conditions in CHF reflect cardiac and laboratory parameters in comparison with non-cachectic patients. Methods: 66 women were enrolled to the study group and underwent meticulous screening, according to recent clinical guidelines, in order to enable CHF and cachexia detection. Body composition was evaluated by bioelectrical impedance analysis (BIA) and laboratory tests were supplemented by analysis of plasma circulating irisin. Results: A negative correlation between irisin concentration and both CRP and TNF-α was recorded (R = −0.362 and R = −0.243; p < 0.05). Irisin concentration positively correlated with EF% (R = 0.253; p = 0.046) and negatively with LVESd, LVEDd and NT-proBNP (R = −0.326, −0.272, and −0.320; p < 0.05). Both low levels of circulating irisin and Capacitance of membrane (Cm) were selected as unfavorable factors affecting cachexia in CHF patients (OR = 1.39 and 34.49; p < 0.05). Combination of Cm, irisin, CRP and albumin demonstrated sensitivity of 93.3% and specificity of 85.3% (AUC = 0.949) for distinguishing between cachectic and non-cachectic CHF patients. Conclusions: Selected parameters reliably reflect cachectic conditions in CHF, and the proposed approach for cachexia based on the combined analysis of at least a few non-invasive markers could offer new opportunities for improving clinical outcomes in CHF patients.

show abstract

Transcoronary concentration gradients of circulating microRNAs in heart failure

Cited by 81 publications

References 35 publications

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls

Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls

Combined detection of miR-21-5p, miR-30a-3p, miR-30a-5p, miR-155-5p, miR-216a and miR-217 for screening of early heart failure diseases

Electrical and Hormonal Biomarkers in Cachectic Elderly Women with Chronic Heart Failure

Contact Info

Product

Resources

About